Navigation Links
FDA Approves ACIPHEX(R) (rabeprazole sodium) 20 mg for Short-Term Treatment of GERD in Adolescents
Date:6/30/2008

her GERD symptoms. The safety and effectiveness of ACIPHEX has not been established for children under the age of 12.

Important Safety Information

ACIPHEX has a well-established safety profile. The most common side effect possibly related to ACIPHEX is headache. Symptom relief does not rule out other serious stomach conditions. Patients on warfarin (such as Coumadin(R)) may need to be monitored more closely by their doctor. To learn more, talk to your doctor and see the full product information at http://www.aciphex.com.

About Eisai Corporation of North America

Eisai Corporation of North America is a wholly-owned subsidiary of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: neurology, gastrointestinal disorders and oncology/critical care.

Eisai Corporation of North America supports the activities of its operating companies in North America. These operating companies include: Eisai Research Institute of Boston, Inc., a discovery operation with strong organic chemistry capabilities; Morphotek, Inc., a biopharmaceutical company specializing in the development of therapeutic monoclonal antibodies; Eisai Medical Research Inc., a clinical development group; Eisai Inc., a commercial operation with manufacturing and marketing/sales functions; MGI PHARMA, INC., an R&D and commercial operation with manufacturing and marketing/sales functions; and Eisai Machinery U.S.A., which markets and maintains pharmaceutical manufacturing machinery.
For more information about Eisai, please visit http://www.eisai.com.

ACIPHEX is a registered trademark of Eisai Co., Ltd.

Coumadin is a registered trademark of Bristol-Myers Squibb Pharma Company.

For Media Inquiries: For Investor In
'/>"/>

SOURCE Eisai Corporation of North America
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related biology technology :

1. FDA Approves CONCERTA(R) (methylphenidate HCI) Extended-release Tablets for Treatment of ADHD (Attention Deficit Hyperactivity Disorder) in Adults
2. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
3. Big Win for Biodiesel: ASTM Approves New Biodiesel Blend Specifications
4. FDA Approves GlaxoSmithKlines AVODART(R) in Combination with Tamsulosin for the Treatment of Symptomatic Enlarged Prostate
5. Arpida Annual General Meeting of Shareholders Approves All Board Proposals
6. FDA Approves MIXJECT(TM), a Convenient, Easy-to-Use Drug Delivery System For Watson Pharmaceuticals TRELSTAR(R) DEPOT and TRELSTAR(R) LA
7. FDA Approves VYVANSE(TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults
8. Maryland Approves Medicaid Reimbursement for ActiPatch(R)
9. Healthcare Coalition Approves Tools to Improve Patient Safety During Transitions of Care
10. Medicare Approves in Home Sleep Apnea Testing
11. 3SBio Inc. Approves Share Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 17, 2013 The paradigm of ‘one ... systems that can help predict the adverse and therapeutic ... Stepaniants, Head of Computational Biology at the Genomics Laboratory, ... to ensure high-quality genomics when used as part of ... to complex data sets to identify key clinical targets ...
(Date:5/17/2013)... 17, 2013 Tooth decay is an epidemic ... signs of the disease. The World Health Organization says that ... of adults have cavities. What are the long-term effects of ... a strong connection between the oral bacterial imbalance and serious ... so rampant, yet it is also 100% preventable? Answer: there ...
(Date:5/16/2013)... In late 2012, Dr. Sarah Hart, of Palm ... China about Appearance Medicine . Although Dr. Hart regularly ... trip to lecture in China, and quite a different experience ... to 12 and 7 million people respectively. Interest in cosmetic ... point in time. As Dr. Hart passed through the Fuzhou ...
(Date:5/16/2013)... May 16, 2013  HealthSparq, a trusted provider ... nation,s largest regional health plans, will debut a ... Plans (AHIP) Institute 2013 conference on June 13. ... showing how health insurance companies across the country ... and marketplace demands for increased healthcare transparency. ...
Breaking Biology Technology:Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 3HealthSparq to Reveal New Healthcare Transparency Benchmark Study at AHIP Institute 2013 2HealthSparq to Reveal New Healthcare Transparency Benchmark Study at AHIP Institute 2013 3
... Inc. (OTC/BB: TBIO) today announced the following Webcast:What: ... Business Update Conference CallWhen: , Thursday, May 12, 2011 ... Live over the Internet -- Simply log on to ... 402-452-5400To access the call via telephone, call 800-895-0198 from ...
... Sciences, Inc. (NASDAQ: CALP ), a leading ... life sciences research for personalized medicine, will be hosting ... 17th and 18th.  This annual event brings together global ... the technologies and discoveries that are transforming the detection ...
... May 5, 2011 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... the development and commercialization of products for central nervous ... the first quarter ended March 31, 2011. ... have made to date in 2011," said Mihael H. ...
Cached Biology Technology:Transgenomic to Hold First Quarter Financial Results Conference Call on May 12, 2011 2Caliper Owners Group and Investor Meeting to Highlight Technologies Enabling Personalized Medicine 2Vanda Pharmaceuticals Reports First Quarter 2011 Results 2Vanda Pharmaceuticals Reports First Quarter 2011 Results 3Vanda Pharmaceuticals Reports First Quarter 2011 Results 4Vanda Pharmaceuticals Reports First Quarter 2011 Results 5Vanda Pharmaceuticals Reports First Quarter 2011 Results 6Vanda Pharmaceuticals Reports First Quarter 2011 Results 7Vanda Pharmaceuticals Reports First Quarter 2011 Results 8
(Date:5/16/2013)... , May 16, 2013 Reportlinker.com ... is available in its catalogue: ... Opportunities, 2018 http://www.reportlinker.com/p01181929/Global-Biometric-Systems-Market-Forecast--Opportunities-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Security_Systems ... old security practises such as photographs, passwords ... of biometric technologies in last few years. ...
(Date:5/15/2013)... In the largest clinical trial to date to examine ... carriers with diseases other than breast and ovarian cancer, ... against advanced pancreatic and prostate cancers. Results of the ... Medicine at the University of Pennsylvania and Sheba Medical ... the American Society of Clinical Oncology,s annual meeting in ...
(Date:5/15/2013)... frontier explorer and world-renowned filmmaker James Cameron has been ... Diego as the recipient of the 2013 Nierenberg Prize ... a presentation on his record-setting DEEPSEA CHALLENGE expedition and ... Friday, May 31, on the UC San Diego campus. ... probe the mysteries and promise of the deep sea ...
Breaking Biology News(10 mins):Global Biometric Systems Market Forecast & Opportunities, 2018 2Global Biometric Systems Market Forecast & Opportunities, 2018 3Global Biometric Systems Market Forecast & Opportunities, 2018 4Global Biometric Systems Market Forecast & Opportunities, 2018 5Global Biometric Systems Market Forecast & Opportunities, 2018 6Global Biometric Systems Market Forecast & Opportunities, 2018 7PARP inhibitor shows activity in pancreatic, prostate cancers among patients carrying BRCA mutations 2James Cameron to be publicly honored with Scripps Nierenberg Prize 2James Cameron to be publicly honored with Scripps Nierenberg Prize 3James Cameron to be publicly honored with Scripps Nierenberg Prize 4
... the latest issue of the journal Nature, scientists at ... of the National Institutes of Health (NIH) describe a ... lead to new ways of thinking about how to ... , Led by immunologist Ronald Germain, M.D., Ph.D., the ...
... A pig used for research at the University of ... will provide the first sequence of the swine genome ... $10 million grant from the U.S. Department of Agriculture ... , Lawrence B. Schook, a professor of animal sciences ...
... Scientists at The University of Texas at Austin have developed ... that surrounds bacteria and plays a role in infection and ... during the course of an infection, cloaking the bacteria from ... the sugars were too slow to catch these rapid changes. ...
Cached Biology News:Chemical guidance of T cells leads to immunologic memory and long-term immunity 2Chemical guidance of T cells leads to immunologic memory and long-term immunity 3Illinois pig to make history as source of first complete swine genome 2Scientists seek to unwrap the sweet mystery of the sugar coat on bacteria 2
Can be used for the quantitative recovery of small amounts of nucleic acids within dilute solutions. 5mg/ml...
... controls for monitoring Aldolase tests. 2 ... with targeted manufacturing values at 4 ... 3 IU/L. 30-day shelf life ... C. Level 1: 3 x 3 ...
APOPTAG® Plastic Coverslips are designed to be custom fitted to the specific APOPTAG® kit application. Each coverslip has 2.5 x 1 dimensions....
Recombinant Mouse sTNF RII/TNFRSF1B...
Biology Products: